Is CHRN a Buy? What to Consider in 2026
Short answer
The bull case for ChronoScale Corporation (CHRN) rests on Riding AI compute demand: ChronoScale sells the raw GPU capacity that AI model builders need, a market that has grown quickly as training and inference workloads expand. Revenue (fiscal 2025, ended May 2025) is ~$84 million, up roughly 191% year over year. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The risks are substantial and stack together. Whether CHRN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
ChronoScale Corporation is a "neocloud," meaning it buys large clusters of NVIDIA GPUs, installs them in data centers, and rents that accelerated compute to companies running artificial intelligence workloads such as model training, inference, and high-performance computing. It began life as the cloud unit of Applied Digital, a data-center developer, and became a separate public company on May 5, 2026, when that cloud business was combined with the former shell of Ekso Bionics Holdings, which then renamed itself ChronoScale and kept the ticker CHRN on the Nasdaq Capital Market. The company is based in Dallas, Texas. In fiscal 2025 (the year ended May 2025) the cloud unit ran about 6,144 GPUs and generated roughly $84 million of revenue, up about 191% year over year, while posting a net loss of about $73 million as it invested to scale. The capital structure is unusual and central to the story. Applied Digital exchanged its cloud business for roughly 138 million ChronoScale shares and still owns about 97% of the company, leaving only a small public float. ChronoScale also pays Applied Digital an ongoing quarterly fee equal to about 1% of its consolidated gross revenue plus other service fees, a related-party arrangement to keep in mind. The stated reason for the split was that the cloud business competes with the same hyperscalers and AI companies Applied Digital wants as data-center leasing customers, so separating the two lets each raise capital and pursue customers independently. Because ChronoScale is newly public, tiny relative to its rivals, and reliant on a very short customer list, its shares have been highly volatile since listing.
What's the case for buying CHRN?
1. Riding AI compute demand
ChronoScale sells the raw GPU capacity that AI model builders need, a market that has grown quickly as training and inference workloads expand. Neocloud revenue overall is forecast by industry analysts to scale into the hundreds of billions of dollars by the early 2030s. As a small, focused operator, ChronoScale is positioned to grow fast off a low base if it can secure GPUs and customers.
2. Independence and capital flexibility
Separating from Applied Digital lets ChronoScale raise its own capital and sign customers that would otherwise conflict with the parent's data-center leasing business. Management framed the split around competition, capital, and concentration. As a standalone name, its financing and expansion decisions are no longer subordinated to the larger parent's priorities.
3. Asset-backed, contract-driven model
The business runs on multi-year GPU capacity commitments, which can provide revenue visibility when large customers sign up. Fiscal 2025 revenue rose about 191% year over year, showing how quickly a single sizable contract can move the top line. The flip side is that the same concentration makes results lumpy and dependent on a few relationships.
4. Access to data-center capacity
As a former Applied Digital unit, ChronoScale has an existing relationship with a large data-center developer, which matters because power and physical shell capacity are the binding constraints in AI infrastructure. That linkage could help it deploy GPUs where competitors struggle to find power, though the arrangement also carries related-party fees and dependence on the parent.
What are the risks to CHRN?
The risks are substantial and stack together. ChronoScale is deeply unprofitable, reporting a net loss of roughly $73 million on about $84 million of revenue in fiscal 2025, and building GPU capacity is extremely capital intensive, so it may need repeated financing. Customer concentration is severe: filings pointed to a very small number of cloud customers, so losing even one would badly hurt revenue. Applied Digital owns about 97% of the stock and collects a fee on gross revenue, leaving public holders with little control and a thin float that can swing sharply. GPUs depreciate fast and can be made obsolete by newer chips, while competition comes from far larger, better-funded rivals and from the hyperscalers themselves. As a newly public company created through a reverse merger with a former shell, it also carries limited standalone operating history and elevated volatility.
How is CHRN valued? (as of July 2026)
Snapshot for CHRN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (fiscal 2025, ended May 2025): ~$84 million, up roughly 191% year over year
- Net income (fiscal 2025): ~-$73 million (net loss)
- GPUs deployed (fiscal 2025): ~6,144 GPUs
- Applied Digital ownership: ~97% of shares outstanding
- P/E ratio: not applicable (company is unprofitable)
- Market cap: ~$2.5 billion (stock ~$18 per share, 52-week range roughly $3 to $28)
Figures are approximate and tied to the asOf date; verify live numbers before acting. ChronoScale has no meaningful earnings multiple because it loses money, so the market is valuing it on future AI compute growth rather than current profit. The stock has been very volatile since its May 2026 listing, and the roughly 97% parent ownership means the small public float can amplify price swings in either direction.
How do you decide if CHRN is a buy?
Rather than asking whether CHRN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CHRN indirectly through an index or sector ETF before adding more.
For the full picture, see the CHRN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CHRN against your real portfolio and see your actual exposure before deciding.
The bottom line on CHRN
The bottom line: ChronoScale Corporation's story right now is Riding AI compute demand, with revenue (fiscal 2025, ended may 2025) at ~$84 million, up roughly 191% year over year. If you believe that narrative continues, the call is about sizing CHRN sensibly and checking overlap with what you own; if you doubt it (the risk: the risks are substantial and stack together.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around CHRN with Walnut
Use ChronoScale Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CHRN a good stock to buy right now?
+
The case for ChronoScale Corporation right now is Riding AI compute demand, with revenue (fiscal 2025, ended may 2025) at ~$84 million, up roughly 191% year over year. If you believe that thesis holds, CHRN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the risks are substantial and stack together. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does ChronoScale Corporation do?
+
ChronoScale Corporation is a 'neocloud,' meaning it buys large clusters of NVIDIA GPUs, installs them in data centers, and rents that accelerated compute to companies running artif
What are the main risks of CHRN?
+
The risks are substantial and stack together. ChronoScale is deeply unprofitable, reporting a net loss of roughly $73 million on about $84 million of revenue in fiscal 2025, and building GPU capacity is extremely capital intensive, so it may need repeated financing. Customer concentration is severe: filings pointed to a very small number of cloud customers, so losing even one would badly hurt revenue. Applied Digital owns about 97% of the stock and collects a fee on gross revenue, leaving public holders with little control and a thin float that can swing sharply. GPUs depreciate fast and can be made obsolete by newer chips, while competition comes from far larger, better-funded rivals and from the hyperscalers themselves. As a newly public company created through a reverse merger with a former shell, it also carries limited standalone operating history and elevated volatility.
What company is CHRN?
+
CHRN is ChronoScale Corporation, a Dallas-based AI cloud compute provider, often called a "neocloud." It rents clusters of GPUs to companies running AI training and inference workloads. It became a public company on Nasdaq on May 5, 2026, after Applied Digital combined its cloud business with the former Ekso Bionics shell and renamed it ChronoScale.
Is CHRN a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is fast growth tied to AI compute demand. The bear case is that ChronoScale loses money, relies on very few customers, is about 97% owned by Applied Digital, and trades with high volatility. Weigh both against your own portfolio before deciding anything.
How does ChronoScale make money?
+
It buys large numbers of NVIDIA GPUs, installs them in data centers, and rents that computing capacity to customers running artificial intelligence workloads. Revenue typically comes from multi-year capacity contracts. In fiscal 2025 it generated roughly $84 million of revenue running about 6,144 GPUs, though it lost money doing so as it invested to scale.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CHRN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.